Cargando...
90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity
Y-ibritumomab tiuxetan (90Y-IT) combines the benefits of a monoclonal antibody with the efficacy of radiation in the treatment of B-cell non-Hodgkin lymphoma (NHL), a remarkably radiosensitive hematologic malignancy. 90Y-IT activity has been well established in the indolent setting, being approved i...
Guardado en:
| Publicado en: | Oncotarget |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Impact Journals LLC
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4884941/ https://ncbi.nlm.nih.gov/pubmed/26657116 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6531 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|